Prestige Consumer Healthcare, Inc. engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. The company is headquartered in Tarrytown, New York and currently employs 600 full-time employees. The company went IPO on 2005-02-10. The firm is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (OTC) health and personal care products to mass merchandisers, drug, food, dollar, convenience, club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets. Its segments include North American OTC Healthcare and International OTC Healthcare. Its diverse portfolio of brands includes Monistat and Summer’s Eve women's health products, BC and Goody's pain relievers, Clear Eyes and TheraTears eye care products, DenTek specialty oral care products, Dramamine motion sickness treatments, Fleet enemas and glycerin suppositories, Chloraseptic and Luden's sore throat treatments and drops, Compound W wart removal products, Boudreaux’s Butt Paste diaper rash ointments, Nix lice treatment products, Debrox earwax remover, and others.
Leveraging in-depth analyst evaluations, we have synthesized critical insights from expert assessments to deliver a robust outlook for PBH. Our analysts highlight strong fundamentals and favorable market sentiment, positioning PBH for significant upside potential in the near term. Based on this comprehensive expert analysis, we maintain a highly optimistic view of this stock. Our conclusion: PBH is a Strong Buy candidate.
PBH stock price ended at $47.57 on 星期四, after dropping 3.18%
On the latest trading day Jun 11, 2026, the stock price of PBH fell by 3.18%, dropping from $49.23 to $47.57. During the session, the stock saw a volatility of 5.14%, with prices oscillating between a daily low of $47.06 and a high of $49.48. On the latest trading day, the trading volume for PBH decreased by 15.6K shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, 571.0K shares were traded, with a market value of approximately $2.2B.